Total Payments
$87,870
2024 Payments
$750.00
Companies
7
Transactions
83
Payment Breakdown by Category
Other$42,991 (48.9%)
Consulting$29,912 (34.0%)
Research$11,524 (13.1%)
Travel$2,754 (3.1%)
Food & Beverage$659.01 (0.7%)
Education$30.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $35,460 | 8 | 40.4% |
| Consulting Fee | $29,912 | 9 | 34.0% |
| Unspecified | $11,524 | 26 | 13.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,531 | 15 | 8.6% |
| Travel and Lodging | $2,754 | 11 | 3.1% |
| Food and Beverage | $659.01 | 13 | 0.7% |
| Education | $30.00 | 1 | 0.0% |
Payments by Type
General
$76,346
57 transactions
Research
$11,524
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $42,222 | 54 | $0 (2024) |
| Horizon Pharma plc | $27,774 | 17 | $0 (2018) |
| Horizon Therapeutics plc | $13,541 | 5 | $0 (2021) |
| Ultragenyx Pharmaceutical Inc. | $3,230 | 2 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $893.33 | 1 | $0 (2020) |
| PTC Therapeutics, Inc. | $105.85 | 1 | $0 (2022) |
| BioMarin Pharmaceutical Inc. | $104.12 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $750.00 | 2 | GENZYME CORPORATION ($750.00) |
| 2023 | $3,250 | 6 | GENZYME CORPORATION ($3,250) |
| 2022 | $8,420 | 21 | GENZYME CORPORATION ($8,314) |
| 2021 | $16,415 | 13 | GENZYME CORPORATION ($13,025) |
| 2020 | $21,627 | 14 | GENZYME CORPORATION ($12,384) |
| 2019 | $5,424 | 5 | Horizon Therapeutics plc ($5,081) |
| 2018 | $19,171 | 16 | Horizon Pharma plc ($18,774) |
| 2017 | $12,813 | 6 | Horizon Pharma plc ($9,000) |
All Payment Transactions
83 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/03/2024 | GENZYME CORPORATION | XENPOZYME (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency • Category: Genetic Disease | ||||||
| 08/27/2024 | GENZYME CORPORATION | XENPOZYME (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency • Category: Genetic Disease | ||||||
| 04/28/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency • Category: Genetic Disease | ||||||
| 04/28/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 04/25/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,250.00 | General |
| Category: Genetic Disease | ||||||
| 02/22/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 02/22/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 02/22/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 12/15/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | — | In-kind items and services | $1,250.00 | Research |
| Study: A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency • Category: Genetic Disease | ||||||
| 10/07/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 09/09/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 08/30/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 05/13/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 05/13/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 05/04/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Genetic Disease | ||||||
| 05/04/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Genetic Disease | ||||||
| 03/24/2022 | PTC Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $105.85 | General |
| 02/10/2022 | GENZYME CORPORATION | XENPOZYME (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency • Category: Genetic Disease | ||||||
| 02/09/2022 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $750.00 | General |
| 02/09/2022 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $740.00 | General |
| 02/09/2022 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $163.60 | General |
| 02/09/2022 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $148.00 | General |
| 02/09/2022 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $117.60 | General |
| 02/09/2022 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $86.04 | General |
| 02/09/2022 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $58.47 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency | GENZYME CORPORATION | $3,250 | 6 |
| A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency | GENZYME CORPORATION | $2,500 | 6 |
| A phase 1-2, multi-center, open-label, ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of recombinant human acid sphingomyelinase | GENZYME CORPORATION | $2,448 | 7 |
| A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Olipudase Alfa in Pediatric Patients Aged <18 Years With Acid Sphingomyelinase Deficiency | GENZYME CORPORATION | $1,750 | 3 |
| A phase 1/2, multi-center, open-label, ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of recombinant human acid sphingomyelinase in pediatric patients aged <18 years with acid sphingomyelinase deficiency | GENZYME CORPORATION | $845.40 | 3 |
| A phase 1-2, multi-center, open-label, ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of recombinant human acid sphingomyelinase in pediatric patients aged less than 18 years with aci | GENZYME CORPORATION | $730.91 | 1 |
About George Diaz, M.D., PH.D
George Diaz, M.D., PH.D is a Pediatrics healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952364952.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, George Diaz, M.D., PH.D has received a total of $87,870 in payments from pharmaceutical and medical device companies, with $750.00 received in 2024. These payments were reported across 83 transactions from 7 companies. The most common payment nature is "Honoraria" ($35,460).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Clinical Genetics (M.D.)
- Location New York, NY
- Active Since 04/10/2006
- Last Updated 03/26/2019
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1952364952
Products in Payments
- RAVICTI (Drug) $41,076
- XENPOZYME (Biological) $10,250
- NO PRODUCT DISCUSSED (Drug) $4,157
- DOJOLVI (Drug) $3,200
- GZ402665 (Drug) $318.00
- NO_PRODUCT (Drug) $158.30
- BMN 165 (Biological) $31.40
- DISEASE STATE (Drug) $25.00
- Naglazyme (Biological) $22.82
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in New York
James Bussel, Md, MD
Pediatrics — Payments: $347,063
Pediatrics $347,063
Rosandra Reich Kaplan, M.d, M.D
Pediatrics — Payments: $300,614
Pediatrics $300,614
Dr. Michael Dolinger, Md, Mba, MD, MBA
Pediatrics — Payments: $143,865
Pediatrics $143,865
Shakeel Modak, Mbbs, MBBS
Pediatrics — Payments: $109,015
Pediatrics $109,015
Kaleb Yohay, M.d, M.D
Pediatrics — Payments: $85,737
Pediatrics $85,737
Dr. Andrew Harris, M.d, M.D
Pediatrics — Payments: $72,344
Pediatrics $72,344